NCT00858364 2022-11-30
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen
Phase 3 Terminated
Clinical Trials
33 trialsNCT03776032 2018-12-20
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
Amgen
Phase 3 Completed
NCT00327535 2016-08-11
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Hoffmann-La Roche
Phase 2 Completed
NCT00401544 2014-01-29
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Amgen
Phase 2 Completed
NCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00144131 2013-05-24
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00135317 2013-05-23
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Amgen
Phase 3 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00111462 2013-05-08
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Amgen
Phase 2 Completed
NCT00540384 2013-05-08
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
Amgen
Phase 1/2 Completed
NCT00118638 2013-04-29
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00540696 2013-04-26
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
Amgen
Phase 2 Completed
NCT00344409 2012-08-31
A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00359840 2012-08-31
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00315484 2011-05-19
Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
Ortho Biotech Products, L.P.
Phase 4 Completed
NCT00239239 2010-03-05
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
Amgen
Phase 2 Completed
NCT00261313 2010-02-26
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
Amgen
Phase 2 Completed
NCT00110955 2010-01-15
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00036023 2009-05-11
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Amgen
Phase 2 Completed
NCT00115167 2009-05-11
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
Amgen
Phase 3 Completed
NCT00117117 2009-03-25
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and AranespĀ®
Amgen
Phase 4 Completed
NCT00120705 2009-03-25
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00095277 2009-03-13
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Amgen
Phase 2 Completed
NCT00117039 2008-10-15
A Study to Evaluate the Effectiveness of AranespĀ® for Cancer Patients With Anemia
Amgen
Phase 4 Completed
NCT00038064 2008-09-15
Anemia in Patients With a Non-Myeloid Malignancy
Amgen
Phase 3 Completed
NCT00119613 2008-08-08
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Amgen
Phase 3 Completed
NCT00111137 2008-02-28
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 3 Completed
NCT00117624 2007-12-28
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
Amgen
Phase 3 Completed
NCT00120679 2007-12-24
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00120692 2007-12-24
Treatment for Patients Suffering From Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00121030 2007-12-24
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Amgen
Phase 2 Completed